PL1814527T3 - Dwuwarstwowe tabletki zawierające telmisartan i amlodypinę - Google Patents
Dwuwarstwowe tabletki zawierające telmisartan i amlodypinęInfo
- Publication number
- PL1814527T3 PL1814527T3 PL05810652T PL05810652T PL1814527T3 PL 1814527 T3 PL1814527 T3 PL 1814527T3 PL 05810652 T PL05810652 T PL 05810652T PL 05810652 T PL05810652 T PL 05810652T PL 1814527 T3 PL1814527 T3 PL 1814527T3
- Authority
- PL
- Poland
- Prior art keywords
- telmisartan
- amlodipine
- bilayer tablet
- bilayer
- tablet
- Prior art date
Links
- 229940043097 telmisartan and amlodipine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04026234 | 2004-11-05 | ||
EP05810652.7A EP1814527B2 (en) | 2004-11-05 | 2005-10-29 | Bilayer tablet comprising telmisartan and amlodipine |
PCT/EP2005/011596 WO2006048208A1 (en) | 2004-11-05 | 2005-10-29 | Bilayer tablet comprising telmisartan and amlodipine |
Publications (2)
Publication Number | Publication Date |
---|---|
PL1814527T3 true PL1814527T3 (pl) | 2014-05-30 |
PL1814527T5 PL1814527T5 (pl) | 2021-08-02 |
Family
ID=35757435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL05810652T PL1814527T5 (pl) | 2004-11-05 | 2005-10-29 | Dwuwarstwowa tabletka zawierająca telmisartan i amlodypinę |
Country Status (30)
Country | Link |
---|---|
US (1) | US20060110450A1 (pl) |
EP (1) | EP1814527B2 (pl) |
JP (1) | JP5134963B2 (pl) |
KR (1) | KR20070085801A (pl) |
CN (2) | CN103083318A (pl) |
AR (1) | AR051618A1 (pl) |
AU (1) | AU2005300787B2 (pl) |
BR (1) | BRPI0517809B1 (pl) |
CA (1) | CA2582049C (pl) |
CY (1) | CY1114957T1 (pl) |
DK (1) | DK1814527T4 (pl) |
EA (1) | EA013053B1 (pl) |
ES (1) | ES2452019T5 (pl) |
HR (1) | HRP20140212T1 (pl) |
IL (1) | IL182926A (pl) |
ME (1) | ME01615B (pl) |
MX (1) | MX366895B (pl) |
MY (1) | MY150758A (pl) |
NO (1) | NO20071514L (pl) |
NZ (1) | NZ555284A (pl) |
PE (2) | PE20061046A1 (pl) |
PL (1) | PL1814527T5 (pl) |
PT (1) | PT1814527E (pl) |
RS (1) | RS53141B (pl) |
SI (1) | SI1814527T1 (pl) |
TW (1) | TWI355268B (pl) |
UA (1) | UA89065C2 (pl) |
UY (1) | UY29188A1 (pl) |
WO (1) | WO2006048208A1 (pl) |
ZA (1) | ZA200702119B (pl) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5110697B2 (ja) * | 2005-06-27 | 2012-12-26 | 第一三共株式会社 | 固形製剤 |
CA2613417C (en) * | 2005-06-27 | 2011-11-29 | Daiichi Sankyo Company, Limited | Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker |
US8518926B2 (en) * | 2006-04-10 | 2013-08-27 | Knopp Neurosciences, Inc. | Compositions and methods of using (R)-pramipexole |
US20070259930A1 (en) * | 2006-04-10 | 2007-11-08 | Knopp Neurosciences, Inc. | Compositions and methods of using r(+) pramipexole |
JP2009537565A (ja) | 2006-05-16 | 2009-10-29 | ノップ ニューロサイエンシーズ、インク. | R(+)およびs(−)プラミペキソール組成とそれを利用する方法 |
EP2465500A1 (en) | 2006-05-16 | 2012-06-20 | Knopp Neurosciences, Inc. | Therapeutically effective amounts of R(+) and S(-) pramipexole for use in the treatment of parkinson's disease |
AR061627A1 (es) * | 2006-06-27 | 2008-09-10 | Novartis Ag | Formas de dosificacion solidas de valsartan, amlodipina, e hidroclorotiazida, y metodo para elaborarlas |
EP1908469A1 (en) | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats |
KR100888131B1 (ko) * | 2006-10-10 | 2009-03-11 | 한올제약주식회사 | 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제 |
KR101247583B1 (ko) * | 2006-12-08 | 2013-03-26 | 한미사이언스 주식회사 | 암로디핀 또는 이의 약제학적 허용가능한 염, 및 로자탄또는 이의 약제학적 허용가능한 염을 함유하는 약제학적조성물 |
US8524695B2 (en) * | 2006-12-14 | 2013-09-03 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
TWI488658B (zh) * | 2006-12-26 | 2015-06-21 | Daiichi Sankyo Co Ltd | 溶出性之改善方法 |
CA2681110A1 (en) | 2007-03-14 | 2008-09-18 | Knopp Neurosciences, Inc. | Synthesis of chirally purified substituted benzothiazole diamines |
EP1970053A1 (en) * | 2007-03-14 | 2008-09-17 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pharmaceutical composition |
JP2012500283A (ja) | 2008-08-19 | 2012-01-05 | ノップ ニューロサイエンシーズ、インク. | (r)−プラミペキソールを使用した組成物並びにその方法 |
JO3239B1 (ar) * | 2008-09-22 | 2018-03-08 | Novartis Ag | تركيبات جالينية من مركبات عضوية |
CZ301299B6 (cs) | 2008-11-24 | 2010-01-06 | Zentiva, A.S. | Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem |
EP2210595A1 (en) | 2009-01-14 | 2010-07-28 | LEK Pharmaceuticals d.d. | Active coating of pharmaceutical dosage forms |
UA102721C2 (uk) | 2009-01-23 | 2013-08-12 | Ханми Сайенс Ко., Лтд. | Тверда фармацевтична композиція, яка містить амлодипін і лозартан, і спосіб її отримання |
TW201109040A (en) | 2009-05-20 | 2011-03-16 | Boehringer Ingelheim Vetmed | Oral suspension comprising telmisartan |
CN102438598B (zh) * | 2009-05-27 | 2015-06-10 | 株式会社茶山医化 | 含有泡腾层的多层片 |
RU2012101792A (ru) * | 2009-06-19 | 2013-07-27 | Нопп Ньюросайенсиз, Инк. | Композиции и способы для лечения бокового амиотрофического склероза |
CN106176745A (zh) * | 2009-06-30 | 2016-12-07 | 赛诺菲 | 包含厄贝沙坦和氨氯地平的固定剂量的固体药用组合物,它们的制备和它们的治疗应用 |
CN101947219B (zh) * | 2009-12-01 | 2012-04-18 | 天津市汉康医药生物技术有限公司 | 一种复方替米沙坦苯磺酸氨氯地平药物组合物及其制备方法 |
CN102085201B (zh) * | 2009-12-08 | 2014-05-07 | 华润双鹤药业股份有限公司 | 阿替洛尔和氨氯地平的双层片剂 |
CN101797250A (zh) * | 2010-04-22 | 2010-08-11 | 重庆市力扬医药开发有限公司 | 一种稳定的复方制剂 |
CN102274223B (zh) * | 2010-06-12 | 2012-10-24 | 重庆市力扬医药开发有限公司 | 含替米沙坦和氨氯地平的复方制剂 |
EA025946B1 (ru) * | 2010-10-27 | 2017-02-28 | Крка, Товарна Здравил, Д. Д., Ново Место | Многослойная фармацевтическая композиция, содержащая телмисартан и амлодипин |
CN102058591A (zh) * | 2010-12-16 | 2011-05-18 | 施慧达药业集团(吉林)有限公司 | 一种左旋氨氯地平和替米沙坦的复方制剂 |
JP2014515359A (ja) * | 2011-05-23 | 2014-06-30 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | ベンズイミダゾール誘導体を含む固形医薬組成物 |
CN103169701B (zh) * | 2011-12-22 | 2015-05-13 | 天津康鸿医药科技发展有限公司 | 替米沙坦氨氯地平双层片及其制备方法 |
US9512096B2 (en) | 2011-12-22 | 2016-12-06 | Knopp Biosciences, LLP | Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
CN103127108B (zh) * | 2012-03-12 | 2015-01-21 | 成都自豪药业有限公司 | 替米沙坦氨氯地平片及其制备方法和用途 |
US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
WO2015006708A1 (en) | 2013-07-12 | 2015-01-15 | Knopp Biosciences Llc | Treating elevated levels of eosinophils and/or basophils |
KR20160027078A (ko) * | 2013-08-02 | 2016-03-09 | 길리애드 사이언시즈, 인코포레이티드 | 라놀라진 및 드로네다론의 제약 조성물 |
ES2813674T3 (es) | 2013-08-13 | 2021-03-24 | Knopp Biosciences Llc | Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b |
PT3033081T (pt) | 2013-08-13 | 2021-06-01 | Knopp Biosciences Llc | Composições e métodos para o tratamento da urticária crónica |
CN103463082A (zh) * | 2013-09-10 | 2013-12-25 | 扬子江药业集团四川海蓉药业有限公司 | 一种替米沙坦氨氯地平双层片及其制备方法 |
KR101910901B1 (ko) * | 2013-11-29 | 2018-10-24 | 한미약품 주식회사 | 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제 |
KR20150111686A (ko) * | 2014-03-26 | 2015-10-06 | 주식회사 종근당 | 산화안정성이 향상된 텔미사르탄 및 (s)-암로디핀을 포함하는 약제학적 제제 |
CN104000821B (zh) * | 2014-06-02 | 2020-06-19 | 浙江华海药业股份有限公司 | 含有替米沙坦和苯磺酸氨氯地平的口服双层片剂及其制备方法 |
EP3185856B1 (en) * | 2014-08-29 | 2018-05-23 | Duchesnay Inc. | Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
CN104188968B (zh) * | 2014-09-23 | 2017-01-18 | 广西壮族自治区药用植物园 | 一种抗高血压的口服片剂及其制备方法 |
JP5871294B1 (ja) * | 2015-02-27 | 2016-03-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 即時放出経口錠剤 |
KR101750689B1 (ko) | 2015-09-15 | 2017-06-26 | 주식회사 종근당 | 약제학적 복합제제 |
KR101710441B1 (ko) * | 2015-12-28 | 2017-02-28 | 신풍제약주식회사 | 안정성 및 용출성이 향상된 정제 |
KR101823071B1 (ko) * | 2016-02-15 | 2018-01-29 | 한림제약(주) | 텔미사르탄-함유 정제의 제조방법 |
JP6411662B2 (ja) * | 2016-05-30 | 2018-10-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 固定容量配合剤 |
CN109562074A (zh) * | 2016-08-11 | 2019-04-02 | 因特欧生物制药有限公司 | 包含替米沙坦的单层片复合制剂 |
CN106420739A (zh) * | 2016-10-31 | 2017-02-22 | 扬子江药业集团四川海蓉药业有限公司 | 一种替米沙坦氨氯地平双层片及其制备方法 |
KR101883664B1 (ko) | 2016-11-29 | 2018-07-31 | 안국약품 주식회사 | 텔미사르탄과 암로디핀을 포함하는 단층 복합정제 및 이의 제조방법 |
CN107519144A (zh) * | 2017-07-25 | 2017-12-29 | 江西中医药大学 | 一种替米沙坦氨氯地平片的制备方法 |
KR20190023940A (ko) | 2017-08-30 | 2019-03-08 | 대원제약주식회사 | 안정성 및 용출율이 개선된 텔미사르탄, 암로디핀 및 로수바스타틴을 함유하는 복합제제 및 그 제조방법 |
KR20190023939A (ko) | 2017-08-30 | 2019-03-08 | 대원제약주식회사 | 텔미사르탄, 암로디핀 및 로수바스타틴을 함유하는 복합제제 및 그 제조방법 |
KR102108396B1 (ko) * | 2018-04-25 | 2020-05-07 | 제일약품주식회사 | 약학적 제제 |
TWI745725B (zh) * | 2019-07-29 | 2021-11-11 | 生達化學製藥股份有限公司 | 速放醫藥組成物 |
EP4093381A1 (en) | 2020-01-20 | 2022-11-30 | Zaklady Farmaceutyczne Polpharma S.A. | Bilayer tablet comprising telmisartan and amlodipine |
CN116898816A (zh) * | 2023-08-31 | 2023-10-20 | 北京百奥药业有限责任公司 | 一种替米沙坦氨氯地平片及其制备方法 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4265847A (en) * | 1978-03-30 | 1981-05-05 | Kirby Pharmaceuticals Ltd | Tabletting process |
DK161312C (da) * | 1982-03-11 | 1991-12-09 | Pfizer | Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden |
US6162802A (en) † | 1992-03-10 | 2000-12-19 | Papa; Joseph | Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor |
US5496831A (en) * | 1994-05-13 | 1996-03-05 | The General Hospital Corporation | Inhibition of insulin-induced adiposis |
US6087386A (en) * | 1996-06-24 | 2000-07-11 | Merck & Co., Inc. | Composition of enalapril and losartan |
US20030077229A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
DE69926750T2 (de) * | 1998-06-17 | 2006-06-29 | Bristol-Myers Squibb Co. | Vorbeugung des hirninfarkts durch kombinierte verabreichung von adp-rezeptor antiblutplättchen und antihypertensiven medikamenten |
AU1042199A (en) * | 1998-11-06 | 2000-05-29 | Boehringer Ingelheim International Gmbh | Antihypertensive medicaments containing lacidipine and telmisartan |
HU226948B1 (en) * | 1999-04-28 | 2010-03-29 | Takeda Pharmaceutical | Use of angiotensin ii antagonist for prevention or therapy of progression of simplex retinopathy or preproliferating retinopathy |
US6784207B2 (en) * | 2000-08-04 | 2004-08-31 | Roche Vitamins Inc. | Phytanic acid derivative compositions |
AT5874U1 (de) * | 2000-12-29 | 2003-01-27 | Bioorg Bv | Pharmazeutische zubereitungen enthaltend amlodipinmaleat |
US20030078190A1 (en) * | 2001-05-25 | 2003-04-24 | Weinberg Marc S. | Methods for tissue protection using highly effective inhibition of the renin-angiotensin system |
US6576256B2 (en) * | 2001-08-28 | 2003-06-10 | The Brigham And Women's Hospital, Inc. | Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
US20030114469A1 (en) * | 2001-09-27 | 2003-06-19 | Cohen David Saul | Combinations |
US20030152622A1 (en) * | 2001-10-25 | 2003-08-14 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral diuretic |
AR037565A1 (es) * | 2001-11-21 | 2004-11-17 | Synthon Bv | Formas de sales de amlodipina y procedimientos para prepararlas. |
IL162754A0 (en) * | 2002-01-16 | 2005-11-20 | Boehringer Ingelheim Pharma | Bilayer pharmaceutical tablet comprising telmisartane and a diuretic and preparation thereof |
AUPS236902A0 (en) * | 2002-05-16 | 2002-06-13 | Northern Sydney Area Health Service | Composition and method for treating hypertension |
EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
US8980870B2 (en) * | 2002-09-24 | 2015-03-17 | Boehringer Ingelheim International Gmbh | Solid telmisartan pharmaceutical formulations |
DE10244681A1 (de) * | 2002-09-24 | 2004-04-08 | Boehringer Ingelheim International Gmbh | Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung |
EP1818056A1 (de) * | 2003-01-16 | 2007-08-15 | Boehringer Ingelheim International Gmbh | Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten |
DE10301371A1 (de) * | 2003-01-16 | 2004-08-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten |
DE10335027A1 (de) * | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
US9029363B2 (en) * | 2003-04-30 | 2015-05-12 | Boehringer Ingelheim International Gmbh | Telmisartan sodium salt pharmaceutical formulation |
WO2005070463A2 (en) * | 2004-01-12 | 2005-08-04 | Sepracor, Inc. | Compositions comprising (s)-amlodipine malate and an angiotensin receptor blocker and methods of their use |
-
2005
- 2005-10-29 DK DK05810652.7T patent/DK1814527T4/da active
- 2005-10-29 RS RS20140027A patent/RS53141B/en unknown
- 2005-10-29 SI SI200531829T patent/SI1814527T1/sl unknown
- 2005-10-29 CA CA2582049A patent/CA2582049C/en not_active Expired - Fee Related
- 2005-10-29 WO PCT/EP2005/011596 patent/WO2006048208A1/en active Application Filing
- 2005-10-29 NZ NZ555284A patent/NZ555284A/en unknown
- 2005-10-29 EP EP05810652.7A patent/EP1814527B2/en active Active
- 2005-10-29 JP JP2007538343A patent/JP5134963B2/ja active Active
- 2005-10-29 BR BRPI0517809-6A patent/BRPI0517809B1/pt active IP Right Grant
- 2005-10-29 KR KR1020077012726A patent/KR20070085801A/ko active Search and Examination
- 2005-10-29 ME MEP-2013-147A patent/ME01615B/me unknown
- 2005-10-29 MX MX2007005235A patent/MX366895B/es active IP Right Grant
- 2005-10-29 EA EA200700977A patent/EA013053B1/ru not_active IP Right Cessation
- 2005-10-29 AU AU2005300787A patent/AU2005300787B2/en active Active
- 2005-10-29 UA UAA200705853A patent/UA89065C2/ru unknown
- 2005-10-29 PT PT58106527T patent/PT1814527E/pt unknown
- 2005-10-29 CN CN2013100152457A patent/CN103083318A/zh active Pending
- 2005-10-29 ES ES05810652T patent/ES2452019T5/es active Active
- 2005-10-29 PL PL05810652T patent/PL1814527T5/pl unknown
- 2005-10-29 CN CNA2005800339289A patent/CN101052381A/zh active Pending
- 2005-11-02 US US11/265,722 patent/US20060110450A1/en not_active Abandoned
- 2005-11-02 MY MYPI20055193 patent/MY150758A/en unknown
- 2005-11-03 PE PE2005001289A patent/PE20061046A1/es not_active Application Discontinuation
- 2005-11-03 UY UY29188A patent/UY29188A1/es not_active Application Discontinuation
- 2005-11-03 PE PE2011000079A patent/PE20110216A1/es not_active Application Discontinuation
- 2005-11-04 AR ARP050104624A patent/AR051618A1/es unknown
- 2005-11-04 TW TW094138683A patent/TWI355268B/zh not_active IP Right Cessation
-
2007
- 2007-03-13 ZA ZA200702119A patent/ZA200702119B/en unknown
- 2007-03-22 NO NO20071514A patent/NO20071514L/no not_active Application Discontinuation
- 2007-05-02 IL IL182926A patent/IL182926A/en active IP Right Grant
-
2014
- 2014-03-07 CY CY20141100180T patent/CY1114957T1/el unknown
- 2014-03-10 HR HRP20140212TT patent/HRP20140212T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL182926A0 (en) | Bilayer tablet comprising telmisartan and amlodipine | |
IL182455A0 (en) | Bilayer tablet | |
IL177536A0 (en) | Multilayer tablet | |
HK1082195A1 (en) | Orally-dispersible multilayer tablet | |
IL217916A0 (en) | Pharmaceutical products | |
IL218117A (en) | A tablet containing saxagliptin and several layers of coating | |
ZA200606812B (en) | Corn event mir604 | |
IL176923A0 (en) | Structured materials and methods | |
HK1101911A1 (en) | Tetrahydrocarbozoles and derivatives | |
IL183944A0 (en) | Combination therapy comprising telmisartan and hydrochlorothiazide | |
ZA200703976B (en) | Pool Chemical Tablet | |
IL178888A0 (en) | Arylphenylamino-, arylphenylamide-, and arylphenylether-sulfide derivatives | |
GB0424323D0 (en) | Tablet | |
IL181938A0 (en) | Lercanidipine capsules | |
ZA200606826B (en) | Compression-coated tablets and manufacture thereof | |
GB0403733D0 (en) | Medicaments | |
GB2426724B (en) | Patterning methods and products | |
PT1584631E (pt) | Macromonómeros de polietilenoglicol copolimerizáveis, sua preparação e aplicação | |
ZA200405240B (en) | Bilayer pharmaceutical tablet comprising telmisartan and diuretic and preparation thereof | |
GB0411624D0 (en) | Products and uses thereof | |
EP1744745A4 (en) | PHARMACEUTICAL NITRONES | |
GB2438839B (en) | Packaging and assemblies | |
EP1816136A4 (en) | GPR7 SELECTIVE LIGAND AND APPLICATION THEREOF | |
ZAA200500028S (en) | Tablet | |
ZAA200500705S (en) | Tablet |